Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clovis Oncology (NASDAQ: CLVS) and Intuitive Surgical (NASDAQ: ISRG)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Clovis Oncology (NASDAQ: CLVS) and Intuitive Surgical (NASDAQ: ISRG).

Clovis Oncology (NASDAQ: CLVS)

Stifel Nicolaus analyst Thomas Shrader reiterated a Buy rating on Clovis Oncology (NASDAQ: CLVS) on June 19 and set a price target of $125. The company’s shares closed yesterday at $95, close to its 52-week high of $96.92.

According to TipRanks.com, Shrader is a 5-star analyst with an average return of 27.3% and a 55.3% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Threshold Pharmaceuticals, and Inovio Pharmaceuticals.

Currently, the analyst consensus on Clovis Oncology is Strong Buy and the average price target is $84, representing a -11.6% downside.

In a report issued on June 13, Leerink Swann also initiated coverage with a Buy rating on the stock with a $85 price target.
Intuitive Surgical (NASDAQ: ISRG)

In a report issued on June 19, Suraj Kalia from Northland Securities reiterated a Sell rating on Intuitive Surgical (NASDAQ: ISRG), with a price target of $600. The company’s shares closed yesterday at $948.94, close to its 52-week high of $963.54.

According to TipRanks.com, Kalia is a 3-star analyst with an average return of 4.5% and a 55.7% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Xtant Medical Holdings, and Edwards Lifesciences.

Intuitive Surgical has an analyst consensus of Moderate Buy, with a price target consensus of $856.42.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.